Finding 970351 (2023-004)

Material Weakness
Requirement
P
Questioned Costs
-
Year
2023
Accepted
2024-04-22
Audit: 304072
Organization: YWCA West Central Michigan (MI)

AI Summary

  • Core Issue: Independent reviews and approvals are missing for key accounting activities, increasing the risk of unauthorized transactions.
  • Impacted Requirements: All significant transactions, including journal entries, payroll, and invoices, must have documented independent reviews and approvals.
  • Recommended Follow-Up: Implement a structured review process for all transactions, ensuring approvals are documented and tracked by designated officials.

Finding Text

#2023-004 – Material Weakness: Independent Review and Approval Condition and Criteria: Independent reviews and approvals are not performed for all significant accounting activities. A procedure should be in place for independent reviews and approvals of significant accounting activities. For all activities, no one individual should have access that allows initiating, recording, authorizing, and reconciling a transaction. Cause/Context: The following transactions are performed without independent review and approval: • Journal entries are posted without a review or approval process. • Formal review of payroll registers is not documented. • Invoices are not regularly reviewed and approved by appropriate department directors. Invoices are also entered into the general ledger with no independent review of the entry. • Percentages used to allocate expenses across grants are not reviewed on at least an annual basis. • Matching amounts required for grants are not independently tracked and reviewed to ensure compliance. Effect: Unauthorized, erroneous, or inappropriate transactions could occur and go unnoticed. Recommendation: The Organization should establish review procedures such that all transactions have proper approval.Views of Responsible Officials and Planned Corrective Actions: The YWCA will implement the following changes in its accounting procedures: 1. Journal entries will be drafted by the Staff Accountant and reviewed by the CFO prior to being posted to the general ledger. The end-of-month-journal-entry spreadsheets will have spaces added for the CFO to indicate approval and date approved. 2. Payroll registers will be reviewed by the CFO each payroll. The end-of-month payroll entry (which encompasses all the payroll entries for the month) will be reviewed by the CFO prior to being uploaded to the MIP accounting software. 3. All invoices will be approved by the appropriate program director and account distribution will be reviewed by the CFO prior to entry into the accounts payable system. 4. Percentages used to allocate expenses across grants will be reviewed and updated annually at the beginning of the fiscal year. The allocation will be approved by the CEO. 5. Matching amounts for grants will be tracked and documented with supporting documentation by the Director of Finance and saved in the appropriate folder within the Finance SharePoint folder

Categories

Matching / Level of Effort / Earmarking Allowable Costs / Cost Principles Material Weakness

Other Findings in this Audit

  • 393863 2023-005
    Significant Deficiency Repeat
  • 393864 2023-006
    Material Weakness
  • 393865 2023-007
    Significant Deficiency
  • 393866 2023-005
    Significant Deficiency Repeat
  • 393867 2023-006
    Material Weakness
  • 393868 2023-007
    Significant Deficiency
  • 393869 2023-005
    Significant Deficiency Repeat
  • 393870 2023-006
    Material Weakness
  • 393871 2023-007
    Significant Deficiency
  • 393872 2023-005
    Significant Deficiency Repeat
  • 393873 2023-006
    Material Weakness
  • 393874 2023-007
    Significant Deficiency
  • 393875 2023-011
    Significant Deficiency Repeat
  • 393876 2023-011
    Significant Deficiency Repeat
  • 393877 2023-011
    Significant Deficiency Repeat
  • 393878 2023-008
    Material Weakness Repeat
  • 393879 2023-009
    Significant Deficiency
  • 393880 2023-010
    Material Weakness
  • 393881 2023-011
    Significant Deficiency Repeat
  • 393882 2023-008
    Material Weakness Repeat
  • 393883 2023-009
    Significant Deficiency
  • 393884 2023-010
    Material Weakness
  • 393885 2023-011
    Significant Deficiency Repeat
  • 393886 2023-008
    Material Weakness Repeat
  • 393887 2023-009
    Significant Deficiency
  • 393888 2023-010
    Material Weakness
  • 393889 2023-011
    Significant Deficiency Repeat
  • 393890 2023-008
    Material Weakness Repeat
  • 393891 2023-009
    Significant Deficiency
  • 393892 2023-010
    Material Weakness
  • 393893 2023-011
    Significant Deficiency Repeat
  • 393894 2023-008
    Material Weakness Repeat
  • 393895 2023-009
    Significant Deficiency
  • 393896 2023-010
    Material Weakness
  • 393897 2023-011
    Significant Deficiency Repeat
  • 393898 2023-008
    Material Weakness Repeat
  • 393899 2023-009
    Significant Deficiency
  • 393900 2023-010
    Material Weakness
  • 393901 2023-011
    Significant Deficiency Repeat
  • 393902 2023-011
    Significant Deficiency Repeat
  • 393903 2023-011
    Significant Deficiency Repeat
  • 393904 2023-011
    Significant Deficiency Repeat
  • 393905 2023-011
    Significant Deficiency Repeat
  • 393906 2023-011
    Significant Deficiency Repeat
  • 393907 2023-004
    Material Weakness
  • 393908 2023-004
    Material Weakness
  • 393909 2023-004
    Material Weakness
  • 393910 2023-004
    Material Weakness
  • 393911 2023-004
    Material Weakness
  • 393912 2023-004
    Material Weakness
  • 393913 2023-004
    Material Weakness
  • 393914 2023-004
    Material Weakness
  • 393915 2023-004
    Material Weakness
  • 393916 2023-004
    Material Weakness
  • 970305 2023-005
    Significant Deficiency Repeat
  • 970306 2023-006
    Material Weakness
  • 970307 2023-007
    Significant Deficiency
  • 970308 2023-005
    Significant Deficiency Repeat
  • 970309 2023-006
    Material Weakness
  • 970310 2023-007
    Significant Deficiency
  • 970311 2023-005
    Significant Deficiency Repeat
  • 970312 2023-006
    Material Weakness
  • 970313 2023-007
    Significant Deficiency
  • 970314 2023-005
    Significant Deficiency Repeat
  • 970315 2023-006
    Material Weakness
  • 970316 2023-007
    Significant Deficiency
  • 970317 2023-011
    Significant Deficiency Repeat
  • 970318 2023-011
    Significant Deficiency Repeat
  • 970319 2023-011
    Significant Deficiency Repeat
  • 970320 2023-008
    Material Weakness Repeat
  • 970321 2023-009
    Significant Deficiency
  • 970322 2023-010
    Material Weakness
  • 970323 2023-011
    Significant Deficiency Repeat
  • 970324 2023-008
    Material Weakness Repeat
  • 970325 2023-009
    Significant Deficiency
  • 970326 2023-010
    Material Weakness
  • 970327 2023-011
    Significant Deficiency Repeat
  • 970328 2023-008
    Material Weakness Repeat
  • 970329 2023-009
    Significant Deficiency
  • 970330 2023-010
    Material Weakness
  • 970331 2023-011
    Significant Deficiency Repeat
  • 970332 2023-008
    Material Weakness Repeat
  • 970333 2023-009
    Significant Deficiency
  • 970334 2023-010
    Material Weakness
  • 970335 2023-011
    Significant Deficiency Repeat
  • 970336 2023-008
    Material Weakness Repeat
  • 970337 2023-009
    Significant Deficiency
  • 970338 2023-010
    Material Weakness
  • 970339 2023-011
    Significant Deficiency Repeat
  • 970340 2023-008
    Material Weakness Repeat
  • 970341 2023-009
    Significant Deficiency
  • 970342 2023-010
    Material Weakness
  • 970343 2023-011
    Significant Deficiency Repeat
  • 970344 2023-011
    Significant Deficiency Repeat
  • 970345 2023-011
    Significant Deficiency Repeat
  • 970346 2023-011
    Significant Deficiency Repeat
  • 970347 2023-011
    Significant Deficiency Repeat
  • 970348 2023-011
    Significant Deficiency Repeat
  • 970349 2023-004
    Material Weakness
  • 970350 2023-004
    Material Weakness
  • 970352 2023-004
    Material Weakness
  • 970353 2023-004
    Material Weakness
  • 970354 2023-004
    Material Weakness
  • 970355 2023-004
    Material Weakness
  • 970356 2023-004
    Material Weakness
  • 970357 2023-004
    Material Weakness
  • 970358 2023-004
    Material Weakness

Programs in Audit

ALN Program Name Expenditures
16.575 Crime Victim Assistance $215,454
14.267 Continuum of Care Program $169,460
16.736 Transitional Housing Assistance for Victims of Domestic Violence, Dating Violence, Stalking, Or Sexual Assault $162,890
93.497 Family Violence Prevention and Services/ Sexual Assault/rape Crisis Services and Supports $103,037
16.017 Sexual Assault Services Formula Program $74,585
93.136 Injury Prevention and Control Research and State and Community Based Programs $56,938
93.671 Family Violence Prevention and Services/domestic Violence Shelter and Supportive Services $42,541
93.558 Temporary Assistance for Needy Families $30,990
16.021 Justice Systems Response to Families $30,768
97.024 Emergency Food and Shelter National Board Program $3,977